Clinical trials: Malaria Falciparum
Malaria,Falciparum, Malaria
CHILD (Child Health and Infection With Low Density) Malaria
This trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
- Trial name
- NCT05567016
- Testing
- Active case detection using molecular testing (ACDm), Passive case detection using molecular testing (PCDm), Control (standard of care)
- Where
- Tanzania
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Dose Escalation PfSPZ-CVac
Background: People get malaria from bites from infected mosquitos. Researchers are studying a vaccine strategy. They will give people malaria parasites by injecting them with live infectious malaria parasites with antimalarial…
- Trial name
- NCT03083847
- Testing
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following…
- Trial name
- NCT02207816
- Testing
- Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
Artesunate-amodiaquine and artemether-lumfantrine are currently being used for the treatment of uncomplicated Plasmodium falciparum in Cameroon.
- Trial name
- NCT04565184
- Testing
- Artesunate-amodiaquine combination, Artemether, Lumefantrine Drug Combination
- Where
- Cameroon
- Volunteers
- 242 people
- Sponsor
- University of Yaounde 1
Malaria (Plasmodium Falciparum), Malaria Falciparum
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
This Phase 1b study will assess the safety, tolerability and pharmacokinetics (PK, this measures the levels of study drug in the body) of a single injection of MMV371 in healthy adult and adolescent participants in Rwanda.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Falciparum, Malaria Infection, Malaria Prophylaxis
- Trial name
- NCT07548021
- Testing
- MMV371
- Where
- Rwanda
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria,Falciparum
Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
The purpose of this study is to compare the gametocytocidal and transmission reducing activity of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine-amodiaquine (ALAQ) with and without a single dose of 0.25mg/kg primaquine…
- Trial name
- NECTAR4 (NCT05550909)
- Testing
- Artesunate-amodiaquine combination, Primaquine Phosphate, Artemether-lumefantrine
- Where
- Mali
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria, Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of…
- Trial name
- NCT07011511
- Testing
- MMV055 Dose 1, MMV055 Dose 2, MMV055 Dose 3
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
This is a randomized, double blind, placebo-controlled, single site, trial of a condensed regimen of PfSPZ Vaccine administered on Days 1, 8 and 29 by direct venous inoculation (DVI) to assess safety, tolerability, immunogenicity…
- Trial name
- NCT04966871
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria
Getting Malaria "Off the Back" of Women and Children in Western Uganda
This is a two-phase, mixed-methods pilot study of insecticide-treated lesus to reduce the incidence of P. falciparum malaria among infants in a rural area of western Uganda.
- Trial name
- NCT04102592
- Testing
- Permethrin-treated Lesu (baby wrap), Untreated Lesu (baby wrap)
- Where
- Uganda
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
To compare Azithromycin plus Chloroquine versus Mefloquine to treat uncomplicated plasmodium falciparum malaria.
- Trial name
- NCT00367653
- Testing
- Azithromycin plus Chloroquine, Mefloquine
- Where
- 8 sites in Burkina Faso, Ghana and 4 more
- Volunteers
- 397 people
- Sponsor
- Pfizer
Drug Resistant Malaria Due to Plasmodium Falciparum
Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa
The antimalarial drugs efficacy and safety study will be conducted in the Clinics and hospital of the Cameroon Development Corporation (CDC) Estates, Tiko Health District, located in a typical forest and rainfall area in the…
- Trial name
- NCT02974348
- Testing
- Arthemeter-lumefantrine, Artesunate mefloquine, Dihydroartemisinin piperaquine
- Where
- Cameroon
- Volunteers
- 300 people
- Sponsor
- University of Bamenda
Falciparum Malaria, Uncomplicated Malaria
Phase II Dose Ranging Study of Artesunate
The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by…
- Trial name
- NCT00459615
- Testing
- Artesunate for Injection
- Where
- 2 sites in Kenya, Thailand
- Volunteers
- 120 people
- Sponsor
- U.S. Army Office of the Surgeon General
Malaria, Pregnancy
Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women
Malaria in pregnancy is potentially fatal to both the mother and the foetus particularly in the primigravidae. Implementation of appropriate control and preventive measures is challenged by the fact that malaria infection in…
- Trial name
- NCT00131703
- Testing
- Amodiaquine, Sulphadoxine-pyrimethamine, Chloroquine
- Volunteers
- 900 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Falciparum Malaria, Antimalarials
The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance
The newly introduced antimalarial drug artemether-lumefantrine is currently recommended as second line antimalarial in Sudan. Recurrent infection after treatment with this drug has been associated with selection of certain genes…
- Trial name
- NCT00440752
- Where
- Sudan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tropical Medicine Research Institute
Malaria
Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa
This study will examine the immune response to the malaria parasite at the cellular level to better understand why people achieve natural immunity to the parasite only after multiple infections and why immunity diminishes rapidly…
- Trial name
- NCT00346346
- Where
- Mali
- Volunteers
- 237 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children
Across sub-Saharan Africa, school-age children bear an under-appreciated burden of malaria. An estimated 200 million school-age children are at risk of malaria and in many areas prevalence of infection exceeds 50%.
- Trial name
- NCT06424002
- Testing
- Mosquirixs, artemether-lumefantrine
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Kamuzu University of Health Sciences
Malaria
Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains
An effective vaccine against malaria is urgently needed to combat the scourge of this disease. Before candidate vaccines can be tested in endemic countries, they are first tested in human volunteers in so-called Controlled Human…
- Trial name
- NCT02149550
- Testing
- NF135 n=5, NF135 n=2, NF135 n=1
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
This study aims to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for…
- Trial name
- KALUMA (NCT05842954)
- Testing
- KLU156, Coartem
- Where
- 33 sites in Burkina Faso, Côte d’Ivoire and 10 more
- Volunteers
- 1,720 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine vaccination visits, has been shown to significantly reduce malaria and anemia in two studies in Tanzania.
- Trial name
- NCT00453856
- Testing
- Sulfadoxine Pyrimethamine
- Where
- Gabon
- Volunteers
- 139 people
- Sponsor
- Albert Schweitzer Hospital, Netherlands
Malaria
Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali
Background: Globally, the Plasmodium falciparum parasite is responsible for at least 247 million acute cases of malaria each year, resulting in about 1 million deaths.
- Trial name
- NCT00889616
- Testing
- BSAM2/Alhydrogel + CPG 7909
- Where
- 2 sites in United States, Mali
- Volunteers
- 154 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)